2181 — Mabpharm Share News
0.000.00%
Last trade - 00:00- HK$1.57bn
- HK$1.82bn
- CNY646.10m
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008
Brief: Mabpharm Says Qian Weizhu Appointed As Vice President
Brief: Mabpharm Gets Approval From Ministry Of Health Of Peru On New Drug Application Of Cmab008
Brief: Mabpharm Says New Drug Application Of Cetuximab Beta Injection Approved By NMPA
Brief: Mabpharm Posts FY Loss Attributable Of RMB209.4 Mln
Brief: Mabpharm Says Hou Sheng Appointed As Executive Director
Brief: Mabpharm Posts HY Loss Attributable RMB100 Million
Brief: Mabpharm Ltd Says Approval From Nmpa On Nda Of Cmab007
Brief: Mabpharm Says Unit Entered Exclusive Commercialization Cooperation Agreement
Brief: Mabpharm Says Loss And Total Comprehensive Expense For Year Attributable RMB210.8 Mln
Brief: Mabpharm Says New Drug Application Of CMAB009 Accepted By NMPA Of China
Brief: Mabpharm Says HY Loss Attributable RMB116.8 Mln
Brief: Mabpharm Says NMPA Approved Clinical Trial Application Of CMAB015
Brief: Mabpharm Announces Approval Of Clinical Trial Application Of Biological Class I New Drug Cmab017
Brief: Mabpharm Says Unit Entered Into An Exclusive Promotion Service Agreement With Kexing Biopharm
Brief: Mabpharm Posts FY Loss Attributable Rmb291.7 Million